

## **Accelerated Access Review**

### Peter Whittington Medtech Senior Policy Adviser





Review of innovative medicines and medical technologies supported by Wellcome Trust

- The challenges facing our health system are significant the need for £22 billion of efficiencies as set out in the NHS Five Year Forward View will require bold ideas and innovation to realise
- The development of innovative therapies and technologies over recent decades has revolutionised health systems throughout the world
- The UK has a proud reputation of being at the forefront of medical innovation that continues to transform care for patients.
- We need to keep pace with the influx of new technologies if we are to sustain our life sciences industry and keep the NHS at the cutting edge of technology.



#### The Accelerated Access Review

- The AAR was launched in November 2014 by Life-Science Minister George Freeman to *"make recommendations to government on reforms to accelerate access for NHS patients to innovative medicines and medical technologies, making our country the best place in the world to design, develop and deploy these products"*
- The review was independently chaired by Sir Hugh Taylor
- The scope of the terms of reference included drugs, devices, diagnostics and digital across development, regulation, assessment and uptake
- The Conservative manifesto included a plan to implement the conclusions of the AAR
- The AAR team worked closely with stakeholders from NHS England, MHRA, NICE, a range of clinical and patient advisors and industry
- The final report was published on October 24<sup>th</sup> <u>https://www.gov.uk/government/organisations/accelerated-access-review</u>



The AAR aims to accelerate access to new drugs, devices, diagnostics and digital products for NHS patients



view of innovative medicines and medical technologies

supported by Wellcome Trust


Office for Life Sciences

Accelerated access to novel life extending/saving medicines and • other therapies Good for Patient involvement; being part of the process from start to finish patients • When the system is being asked to make significant efficiencies, • Good for the we need innovation more than ever, to improve outcomes, NHS productivity and to improve long term sustainability Good for Embedding them and their patient populations in the process from research start to finish charities and organisations Good for Speeding up the pathway **businesses** Simplifying the pathway ٠ and UK Earlier access and better uptake • growth



Life Sciences

Patient involvement is an overarching theme – from the beginning of the pathway to the end



- Transparent and visible knowledge and information on local variations in uptake of innovation to support accountability and decision making
- A set of "*I*" statements should be used as principles to underpin the work of the innovation partnership and its constituent bodies.

http://www.nationalvoices.org.uk/node/1581



Review of innovative medicines and medical technologies supported by Wellcome Trust







Life Sciences

# The final report makes recommendations in five key areas



Review of innovative medicines and medical technologies supported by Wellcome Trust

The Accelerated Access Review aims to work with clinicians to

- speed up access to innovative drugs, medical devices and diagnostics, and digital health for NHS patients
- grow the UK life sciences industry

Patients, clinicians and charities should be the key drivers in the development, prioritisation, evaluation and adoption of innovation

A **new accelerated access pathway** to prioritise strategically important innovation for the benefit of patients and the NHS

Open and transparent pathways for all health technologies, bringing forward medtech, digital and diagnostics which deliver more for less Improved commercial capability to deliver better value

- Commitment to driving through innovation
  - woven into NHS planning
- increased capacity
- clinical leadership
- · adoption incentives

AHSN network promotes and supports local innovation, coordinating across the system Research-led trusts champion adoption and diffusion



New Accelerated Access Partnership brings together key parts of the health system to provide a single source of national-level guidance to all innovators and oversee the innovation pathway




Office for

Life Sciences

## An Accelerated Access Partnership will Access align national bodies around innovation

supported by Wellcome Trust





- Government is now considering the recommendations carefully and will provide a formal response in due course.
- OLS will engage with stakeholders over the next few months to consider Sir Hugh Taylor's recommendations and identify where partners can best focus collective efforts to maximum benefit.